3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
"3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21)
Concept/Terms
U-50488- U-50488
- U 50488
- U50488
- U50488H
- U-50,488H
- U 50,488H
- U50,488H
- U-50488H
- U 50488H
Below are MeSH descriptors whose meaning is more general than "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer".
Below are MeSH descriptors whose meaning is more specific than "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer".
This graph shows the total number of publications written about "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" by people in Harvard Catalyst Profiles by year, and whether "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 0 | 3 | 3 |
1999 | 0 | 1 | 1 |
2006 | 1 | 0 | 1 |
2007 | 0 | 1 | 1 |
2010 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2013 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
Below are the most recent publications written about "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" by people in Profiles.
-
Interactive effects of (±)-trans-U50488 and its stereoisomers with cannabinoids. Pharmacol Biochem Behav. 2021 08; 207:173218.
-
Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats. Int J Neuropsychopharmacol. 2019 11 01; 22(11):735-745.
-
Females are less sensitive than males to the motivational- and dopamine-suppressing effects of kappa opioid receptor activation. Neuropharmacology. 2019 03 01; 146:231-241.
-
Effects of the psychotomimetic benzomorphan N-allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice. Pharmacol Biochem Behav. 2016 09; 148:69-75.
-
Dynorphin Controls the Gain of an Amygdalar Anxiety Circuit. Cell Rep. 2016 Mar 29; 14(12):2774-83.
-
Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats. Biol Psychiatry. 2014 Aug 01; 76(3):213-22.
-
Sex differences in U50,488H-induced phosphorylation of p44/42 mitogen-activated protein kinase in the guinea pig brain. Neuroscience. 2012 Oct 25; 223:447-56.
-
Stimulation of peripheral kappa opioid receptors inhibits inflammatory hyperalgesia via activation of the PI3K?/AKT/nNOS/NO signaling pathway. Mol Pain. 2012 Feb 08; 8:10.
-
Stress-induced activation of the dynorphin/?-opioid receptor system in the amygdala potentiates nicotine conditioned place preference. J Neurosci. 2012 Jan 25; 32(4):1488-95.
-
?FosB enhances the rewarding effects of cocaine while reducing the pro-depressive effects of the kappa-opioid receptor agonist U50488. Biol Psychiatry. 2012 Jan 01; 71(1):44-50.